Rare Ventures, a First-of-its-kind Platform for Accelerating Rare Disease Therapies, Launches in Pittsburgh
Developing treatments for rare diseases presents many challenges: small patient populations, fragmented data and long, complex paths to new therapies. But rare doesn’t mean few. More than 400 million people worldwide live with a rare disease, yet about 95% of the 10,000+ rare diseases don’t have an approved treatment.To help change that, Carnegie Mellon University is a founding partner in a Pittsburgh-based partnership that brings together leaders in medicine, biotechnology…

